Retention time raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-12-30. Anything still debated is marked as such rather than presented as settled.
Regulatory and pharmacopeial texts shape how HPLC testing is performed and documented. The International Council for Harmonisation provides validation guidance, while pharmacopeias publish general chromatography chapters and monographs for specific materials. Accreditation standards such as ISO/IEC 17025 address laboratory competence and traceability. Inspectors may review instrument qualification, analyst training, reference material control, and electronic records. Open questions include how best to validate methods for new complex products and how to handle automated data processing. Laboratories generally resolve these issues through risk assessment, method lifecycle management, and documented scientific justification.
In quality control laboratories, HPLC testing supports batch release, raw material checks, stability studies, and impurity profiling. A validated method defines sample preparation, instrument settings, calibration, and acceptance criteria. Analysts compare results with specifications and investigate out-of-specification outcomes before a batch is approved. Documentation includes chromatograms, integration records, audit trails, and reagent details. Because results influence product decisions, laboratories follow formal quality systems and data integrity rules. The exact tests and limits depend on the material, its intended use, and the applicable regulatory framework.
Method validation examines whether an HPLC procedure is suitable for its intended purpose. Common parameters include accuracy, precision, specificity, linearity, range, detection limit, quantification limit, and robustness. Accuracy describes closeness to a true or accepted value, while precision describes agreement among repeated measurements. Specificity shows whether the method can measure the analyte without interference from related substances. Robustness tests small deliberate changes in flow, temperature, or solvent composition. Validation is not a one-time event; methods may need partial revalidation after changes to instruments, columns, sample handling, or specification limits. Regulatory guidance provides frameworks, but some details remain method-specific.
Key performance measures include retention time, peak area, peak height, resolution, tailing factor, and plate count. Retention time helps identify a peak under fixed conditions, but confirmation often requires a second method or detector. Peak area and height relate to concentration through calibration curves, which may be linear or nonlinear depending on the detector response. Resolution describes separation between adjacent peaks, while tailing factor and plate count describe peak shape and column efficiency. Performance checks verify these values before and during a run to confirm that the instrument is performing within limits.
High-performance liquid chromatography testing separates components of a liquid sample by forcing a mobile phase through a packed column. The stationary phase inside the column interacts with analytes to different degrees, so each compound exits at a characteristic retention time. A pump delivers solvent at controlled flow and pressure, while an injector introduces a precise sample volume. Detectors such as ultraviolet-visible, fluorescence, refractive index, or mass spectrometric instruments record the separated bands. The resulting chromatogram provides qualitative and quantitative information about the mixture.
| Property | Value | Notes |
|---|---|---|
| Primary guidance | ICH Q2(R2) | Analytical procedure validation |
| Compendial chapter | USP <621> | Chromatography general chapter |
| Validation parameter | Accuracy | Closeness to accepted true value |
| System suitability check | Peak resolution | Ensures separation between adjacent peaks |
| Data record | Audit trail | Supports data integrity and traceability |
Laboratories apply HPLC testing across pharmaceutical, food, environmental, and industrial chemistry. The method can measure active ingredients, impurities, additives, preservatives, and degradation products. Sample preparation often includes dilution, filtration, and sometimes extraction or derivatization. The choice of column, mobile phase, pH, temperature, and detector depends on the analytes and matrix. Results are compared with reference standards to assign identity and concentration. Method suitability is judged by resolution, precision, and accuracy.
HPLC testing is not a single fixed procedure; it is a family of separation modes. Reversed-phase, normal-phase, ion-exchange, size-exclusion, and affinity chromatography each suit different analyte properties. Reversed-phase methods dominate because they handle many neutral and moderately polar compounds. Detection can be optical, electrochemical, or mass spectrometric, and the detector dictates what information is available. Coupling with mass spectrometry increases selectivity and enables identification when standards are unavailable. The technique cannot separate every mixture without adjustment.
HPLC testing is an analytical technique used to separate, identify, and quantify components in a liquid sample. It relies on a pressurized mobile phase that carries the sample through a column packed with stationary phase. Different compounds travel at different rates because of interactions with the stationary and mobile phases. The resulting signal versus time is a chromatogram. Peak position indicates identity under specified conditions, while peak area or height relates to amount.
Detection in HPLC testing commonly relies on ultraviolet-visible absorbance, fluorescence, refractive index, or mass spectrometry. A diode array detector records full spectra across a wavelength range, which helps identify co-eluting peaks. Mass spectrometry provides mass-to-charge ratios and can confirm molecular identity at low concentrations. The choice of detector depends on analyte structure, required sensitivity, and whether quantitation or identification is the goal. No single detector works for every compound, and method development often compares responses before selecting one.
High-performance liquid chromatography is an analytical technique that separates components of a liquid sample by passing it through a packed column under pressure. A pump delivers a mobile phase at a controlled flow rate, and an injector introduces the sample into the stream. Differences in interaction with the stationary phase cause analytes to migrate at different rates. Detectors record elution as peaks, and a data system converts signals into a chromatogram. The method is suited to compounds that dissolve in a liquid and are not volatile enough for gas chromatography.
== Nomenclature == Metastable isomers of a particular isotope are usually designated with an "m". This designation is placed after the mass number of the atom. For example, cobalt-58m1, or 58m127Co, is an isomer of cobalt-58. Here, 27 is the atomic number of cobalt, 58 is the total number of nucleons (meaning it has 31 neutrons), "m" means it is an isomer, and "m1" means it is the first (lowest above the ground state) metastable isomer. For isotopes with more than one metastable isomer, "indices" are placed after the designation, and the labeling becomes m1, m2, m3, and so on. Increasing indices, m1, m2, etc., correlate with increasing levels of excitation energy stored in each of the isomeric states (e.g., hafnium-178m2, or 178m272Hf). The index may be omitted if only one isomer is relevant in-context. For fission isomers, use "f" rather than "m".
=== Central nervous system === Adropin is produced in the brain, particularly in the hypothalamus. The hypothalamus is a crucial region for the regulation of various physiological processes, including metabolism and energy balance. The presence of adropin in the brain suggests that it may have additional roles in the central nervous system, although the specifics are still being explored.
== Mathematical work == Abel's work on elliptic functions was built on Legendre's, and some of Gauss's work in statistics and number theory completed that of Legendre. He developed, and first communicated to his contemporaries before Gauss, the least squares method which has broad application in linear regression, signal processing, statistics, and curve fitting; this was published in 1806 as an appendix to his book on the paths of comets. Today, the term "least squares method" is used as a direct translation from the French "méthode des moindres carrés". His major work is Exercices de Calcul Intégral, published in three volumes in 1811, 1817 and 1819. In the first volume he introduced the basic properties of elliptic integrals, beta functions and gamma functions, introducing the symbol Γ and normalizing it to Γ(n+1) = n!. Further results on the beta and gamma functions along with their applications to mechanics – such as the rotation of the earth, and the attraction of ellipsoids – appeared in the second volume. In 1830, he gave a proof of Fermat's Last Theorem for exponent n = 5, which was also proven by Lejeune Dirichlet in 1828. In number theory, he conjectured the quadratic reciprocity law, subsequently proved by Gauss; in connection to this, the Legendre symbol is named after him. He also did pioneering work on the distribution of primes, and on the application of analysis to number theory. His 1798 conjecture of the prime number theorem was rigorously proved by Hadamard and de la Vallée-Poussin in 1896.
=== Current === There are currently 67 territorial authorities. Before the Auckland Council "super merge" in November 2010, there were 73 territorial authorities. Before the Banks Peninsula District Council merged with the Christchurch City Council in 2006, there were 74 territorial authorities.
== Interactions == A combination of ACE inhibitor with other drugs may increase effects of these drugs, but also the risk of adverse effects. Commonly reported adverse effects of drug combination with ACE inhibitor are acute renal failure, hypotension, and hyperkalemia. Drugs interacting with ACE inhibitor should be prescribed with caution. Special attention should be given to combinations of ACE inhibitor with diuretics (especially potassium-sparing diuretics), NSAIDs, anticoagulants, cyclosporine, DPP-4 inhibitors, and potassium supplements Angiotensin II receptor antagonists (ARBs) should not be used with ACE inhibitors. Dual RAAS inhibitor therapy (ACE inhbitors, ARBs, direct renin inhibitors, or mineralocorticoid receptor antagonists) has been found to significantly increase the risk of developing kidney damage and hyperkalemia. Potassium supplementation should be used with caution and under medical supervision owing to the hyperkalemic effect of ACE inhibitors. Concomitant use with cyclooxygenase inhibitors tends to decrease ACE inhibitor's hypotensive effect.
Sources: en.wikipedia.org
The risk of lung cancer is highly influenced by smoking, with up to 90% of diagnoses being attributed to tobacco smoking. The risk of developing lung cancer increases with the number of years smoked and the number of cigarettes smoked per day. Smoking can be linked to all subtypes of lung cancer. Small-cell carcinoma (SCLC) is the most closely associated with almost 100% of cases occurring in smokers. This form of cancer has been identified with autocrine growth loops, proto-oncogene activation and inhibition of tumor suppressor genes. SCLC may originate from neuroendocrine cells located in the bronchus called Feyrter cells. The risk of dying from lung cancer before age 85 is 22% for a male smoker and 12% for a female smoker, in the absence of competing causes of death. The corresponding estimates for lifelong non-smokers are a 1.1% probability of dying from lung cancer before age 85 for a man of European descent and a 0.8% probability for a woman. American epidemiologist and biologist E. Cuyler Hammond (1912–1986) was one of the first researchers to establish a link between smoking and lung cancer.
The 25 April 1953 issue of the journal Nature published a series of five articles giving the Watson and Crick double-helix structure DNA and evidence supporting it. The structure was reported in a letter in which they stated, "It has not escaped our notice that the specific pairing we have postulated immediately suggests a possible copying mechanism for the genetic material." This letter was followed by a letter from Franklin and Gosling, which was the first publication of their own X-ray diffraction data and of their original analysis method. Then followed a letter by Wilkins and two of his colleagues, which contained an analysis of in vivo B-DNA X-ray patterns, and which supported the presence in vivo of the Watson and Crick structure. In April 2023, scientists, based on new evidence, concluded that Rosalind Franklin was a contributor and "equal player" in the discovery process of DNA, rather than otherwise, as may have been presented subsequently after the time of the discovery. In 1962, after Franklin's death, Watson, Crick, and Wilkins jointly received the Nobel Prize in Physiology or Medicine. Nobel Prizes are awarded only to living recipients. A debate continues about who should receive credit for the discovery. In an influential presentation in 1957, Crick laid out the central dogma of molecular biology, which foretold the relationship between DNA, RNA, and proteins, and articulated the "adaptor hypothesis". Final confirmation of the replication mechanism that was implied by the double-helical structure followed in 1958 through the Meselson–Stahl experiment.
== Case studies == The combination of the longevity of sugiol in environmental samples and its presence in only specific families of plants make it an excellent biomarker. Detection of sugiol in combination with other biomarkers like ferruginol or other diterpenes can also help to bolster the identification of the sample, as well as to narrow the scope of possible identities to only a few specific conifer families. Sugiol has been utilized in the identification of extinct plant taxa such as Protopodocarpoxylon, and Taxodioxylori gypsaceum.
This species is of typical elongated tetra appearance; it is of plain basic coloration, but with two distinct, adjacent, longitudinal stripes, white above black. The eye has two thin but distinctive color bands across the top, red above yellow. It grows to a maximum overall length of approximately 4 cm (1.6 in). Befitting its common name, it slightly resembles the neon tetra, which belongs to a different genus (Paracheirodon). Females are often larger than males. The variety named Diamond or Brilliant does not have a white stripe but instead displays more reflective scales around the head. The fish's natural diet consists of small invertebrates and plants. H. herbertaxelrodi is commonly kept as an aquarium fish by hobbyists. The black neon tetra is sometimes called the black tetra, but that name more properly refers to a different species, Gymnocorymbus ternetzi.
Sources: en.wikipedia.org
System suitability is a set of checks performed before and during an HPLC run to confirm that the instrument and method are working as expected. It may include retention time repeatability, resolution between peaks, peak symmetry, and signal intensity. Failing suitability criteria usually invalidates the run.
An HPLC method is typically validated before its routine use and revalidated in part when significant changes affect the method. Regulators do not set a universal calendar interval. The need for revalidation depends on the change, its risk, and the applicable guidance.
Validation establishes that a method is suitable for its intended purpose, often through a planned study. Verification confirms that a laboratory can reproduce a previously validated or compendial method under its own conditions. Verification is usually narrower than full validation.
It measures the amounts and identities of compounds in liquid samples by separation and detection. Depending on the detector and reference standards, results can be qualitative or quantitative. The technique is used in fields such as pharmaceutical analysis, food safety, and environmental monitoring.